8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer

U.Hoch; L.Masuoka; D.Maslyar; D.Von Hoff

首页> 外文期刊>European Journal of Cancer Supplements >8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer

【24h】

8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer

机译：8015 NKTR-102在卵巢癌中显示出非临床和1期临床抗肿瘤活性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
U.Hoch; L.Masuoka; D.Maslyar; D.Von Hoff;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer [J] . U.Hoch, L.Masuoka, D.Maslyar, European Journal of Cancer Supplements . 2009,第2期

机译：8015 NKTR-102在卵巢癌中显示出非临床和1期临床抗肿瘤活性
2. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models [J] . Amanda F Baker, Neale T Hanke, Barbara J Sands, Journal of experimental & clinical cancer research : . 2014,第1期

机译：卡非佐米在临床前非小细胞和小细胞肺癌模型中显示出广泛的抗肿瘤活性
3. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. [J] . Ryan CJ, Smith MR, Fong L, Journal of Clinical Oncology . 2010,第9期

机译：CYP17抑制剂乙酸阿比特龙酯的I期临床试验证明了在接受酮康唑治疗的去势抵抗性前列腺癌患者中的临床活性。
4. Galangin Enhances Gold Nanoparticles as Anti-Tumor Agents Against Ovarian Cancer Cells [C] . Ahmed M. Al-Shammari, Hassan Al-Saadi, Shaimaa M Al-Shammari, International Conference on Materials Engineering and Science . 2020

机译：Galangin增强金纳米粒子作为针对卵巢癌细胞的抗肿瘤剂
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models [O] . Amanda F Baker, Neale T Hanke, Barbara J Sands, 2014

机译：卡非佐米在临床前非小细胞和小细胞肺癌模型中显示出广泛的抗肿瘤活性
7. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results [O] . Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, 2021

机译：腹膜内癌症，持续性或复发性卵巢癌，输卵管癌症或原发性腹膜癌患者的最大耐受剂量和抗肿瘤活性：阶段研究结果

8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer

著录项

相似文献

相关主题

期刊订阅